Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G2204
- Development stage
- Preclinical
- Lead developer
- BC World Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**G2204** is a preclinical, orally administered small-molecule candidate from BCWorld Pharma for hyperlipidemia combination therapy. It is described as an orally disintegrating tablet; its constituent active ingredients, molecular targets, and mechanism of action have not been publicly disclosed.
Beyond the preview
Go deeper on G2204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G2204.